Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes.

What Was Tested

This randomized controlled trial looks at Glucagon.

Hyperglycemia is the major risk factor for microvascular complications in type 2 diabetes mellitus (T2DM) patients.

This randomized controlled clinical trial aimed to investigate T2DM patients with microvascular complications with regard to possible relations among serum clusterin (CLU), amylin, secreted frizzled-related protein-4 (SFRP-4), glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) activities.

Who Took Part

The abstract describes 2 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Subject groups were defined as follows: T2DM without complications (n=25, F/M=9/16, age 53.9±11.1 years); T2DM+Retinopathy (n=25, F/M=13/12, age 63.8±7.1 years); T2DM+Nephropathy (n=25, F/M=13/12, age 58.7±14.4 years); T2DM+Neuropathy (n=25, F/M=15/10, age 63.2±9.6 years); and healthy control subjects (HC) (n=25).

CLU, amylin, SFRP-4, DPP-4 and GLP-1 (total and active) activities were measured and compared in blood samples from type 2 diabetic patients with and without microvascular complications.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Diabetic Nephropathies, Diabetic Retinopathy, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1 and Hyperglycemia.

What This Means in Plain Language

The paper is a randomized study of Glucagon in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 1 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Clinical and investigative medicine. Medecine clinique et experimentale), a journal based in Canada.

More context: the Glucagon compound page, all human trials.